![GO TO CMA Home](../../../images-site/navbar-cmalogo.gif)
![GO TO Inside CMA](../../../images-site/navbar-inside.gif)
![GO TO Advocacy and Communications](../../../images-site/navbar-advocacy.gif)
![GO TO Member Services](../../../images-site/navbar-member.gif)
![GO TO Publications](../../../images-site/navbar-publications.gif)
![GO TO Professional Development](../../../images-site/navbar-prodev.gif)
![GO TO Clinical Resources](../../../images-site/navbar-clinical.gif)
![](../../../images-site/navbar-8space.gif)
![GO TO What's New](../../../images-site/navbar-whatsnew.gif)
![GO TO Contact CMA](../../../images-site/navbar-contact.gif)
![GO TO Web Site Search](../../../images-site/navbar-sitesearch.gif)
![GO TO Web Site Map](../../../images-site/navbar-sitemap.gif)
|
|
![](../../../images-site/nav-j-linkhead.gif)
|
![CMAJ](../../headers/h-cmaj.gif)
![CMAJ - January 26, 1999](issue-2.gif) ![](../../../images-site/navbar-8space.gif) ![](../../../images-site/nav-linksub.gif)
Prostate cancer: 9. Treatment of advanced disease
Table 2: Indications for use of anti-androgens |
To prevent the flare phenomenon during the first month of LH-RH agonist treatment:
cyproterone acetate (50 mg twice daily) plus DES (0.1 mg daily)
or cyproterone acetate (150 mg orally, twice daily)
or cyproterone acetate (150 mg orally, twice daily)
or a nonsteroidal anti-androgen
To treat hot flushes after medical or surgical castration:
cyproterone acetate (50 mg once daily)
To treat biochemical (indicated by rising PSA level) or clinical progression of disease in patients treated with LH-RH agonists, orchiectomy or low-dose cyproterone and mini-dose DES:
3-month trial with a nonsteroidal anti-androgen (bicalutamide, flutamide
or nilutamide),to be continued only if there is a decrease in serum
PSA level |
Note: PSA = prostate-specific antigen. |
[Return to text]
![](../../../images-site/el-up.gif)
|